8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Apr 10, 2026·SEC
Lantern Pharma Inc.(LTRN)Earnings, Financials & Key Ratios
LTRN•NASDAQ
$3.86
Price updated Jun 27, 2026
AboutLantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Show more
- Revenue$0
- EBITDA-$18M+19.1%
- Net Income-$17M+17.6%
- EPS (Diluted)-1.57+99.9%
- ROE-0.52%+99.2%
LTRN Price & Volume
Lantern Pharma Inc. (LTRN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Long-Term Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Dependency
Key Thesis Takeaways
- Lantern Pharma remains in a high-risk clinical development phase, characterized by a total absence of commercial revenue and a reliance on external capital to fund its RADR platform.
- The company's financial trajectory is defined by consistent quarterly operating losses, which peaked at $5.9 million in 2024Q4, and a rapidly eroding asset base that fell from $43.6 million in 2023Q4 to $7.2 million by 2026Q1.
- Investors should monitor the company's ability to achieve clinical milestones, as the current cash burn rate and lack of operational leverage suggest significant dilution risks and potential funding vulnerabilities.
Verdict Logic
the company's reliance on capital markets is underscored by a consistent quarterly cash burn that has reduced total assets from $43.6 million in 2023Q4 to $7.2 million in 2026Q1.
LTRN Growth Metrics
Lantern Pharma Inc. (LTRN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM19.95%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM21.2%
Return on Capital
10 Years-124.41%
5 Years-31.8%
3 Years-36.28%
Last Year-0.55%
LTRN Recent Earnings
Lantern Pharma Inc. (LTRN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.30+16.7%
$0.36
Rev
—
—
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.36+21.7%
$0.46
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.39+15.2%
$0.46
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.40+24.5%
$0.53
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.30vs $0.36+16.7% | — |
| Q2 2026 | Mar 30, 2026 | $0.36vs $0.46+21.7% | — |
| Q4 2025 | Nov 12, 2025 | $0.39vs $0.46+15.2% | — |
| Q3 2025 | Aug 13, 2025 | $0.40vs $0.53+24.5% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Lantern Pharma Inc. (LTRN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.86 | $49.25M | -2.46 | — | — | -0.52% | — | |
| $0.98 | $613.76K | -0.21 | -67.7% | -1319.55% | -105.46% | — | |
| $0.15 | $2.33M | -0.06 | -15.77% | -183.93% | — | — | |
| $1.83 | $110.39M | -3.27 | — | — | -0% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $3.52 | $1.57B | -2.44 | 26.92% | -844.46% | -54.32% | — |
Compare LTRN vs Peers
Lantern Pharma Inc. (LTRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LTRN SEC Filings & Documents
Lantern Pharma Inc. (LTRN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when LTRN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LTRN Frequently Asked Questions
Lantern Pharma Inc. (LTRN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is LTRN profitable?
Lantern Pharma Inc. (LTRN) reported a net loss of $15.9M for fiscal year 2025.
Dividend & Returns
What is LTRN's return on equity?
Lantern Pharma Inc. (LTRN) has a return on equity (ROE) of -0.5%. Negative ROE indicates the company is unprofitable.
What is Lantern Pharma Inc.'s free cash flow?
Lantern Pharma Inc. (LTRN) had negative free cash flow of $15.1M in fiscal year 2025, likely due to heavy capital investments.